SUMMARY – CORE A (Administration Core) The "mRNA Vaccines for C. difficile Suppression” program (mVACS) consists of a highly interactive team of investigators who are seeking to develop an mRNA vaccine platform to provide protection against Clostridioides difficile-associated infection and disease. Project 1 is the engine for generating and testing modified mRNA vaccines (Project 1 – Vaccine Development). This effort is accelerated and guided by projects exploring strain diversity and microbial ecology (Project 2 – Antigen Discovery) and the mucosal adaptive immune response to natural infection (Project 3 – Immunology). Supporting these three projects are two scientific cores that will provide expertise, technical skills, and analysis of large deep-sequencing datasets (Core B - Genomics Core), and collect samples for a patient cohort (Core C - Clinical Core). Core A (Administrative Core) is the logistical and organizational component of the program that will handle regular inter-project communication and ensure seamless exchange of data and information. Core A (Administrative Core) is co-led by the mVACS program directors Dr. Bushman and Dr. Weissman. Their primary objectives will be to monitor the scientific progress of the program, oversee distribution of resources, stimulate project interactions and data integration, ensure compliance with NIH guidelines, and promote the scientific career development of the mVACS team.